News Conference News EAS 2018 Glucose and Beyond? Experts Debate Optimal Targets for Managing CV Risk in Diabetics Yael L. Maxwell May 16, 2018
News Conference News EAS 2018 ORION 1 Data Show Lipoprotein-Lowering Beyond LDL Cholesterol With Injectable Inclisiran Yael L. Maxwell May 14, 2018
News Conference News EAS 2018 EAS Consensus Document Examines Safety of Statins Beyond Muscle Symptoms Yael L. Maxwell May 11, 2018
News Conference News EAS 2018 Unlocking Lp(a): Baseline Levels Matter, but So Too Does Absolute Reduction Yael L. Maxwell May 08, 2018
News Conference News EAS 2018 Can Clinicians Really Put a Stop to Atherosclerosis? Experts Explore the How and When of CVD Prevention Yael L. Maxwell May 07, 2018
Presentation EAS 2018 LPA variants, risk of coronary disease, and estimated clinical benefit of lipoprotein(a) lowering therapies: a Mendelian randomization analysis Presenter: Brian A. Ference May 07, 2018
Presentation EAS 2018 Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial Presenter: Michelle L. O’Donoghue May 07, 2018
News Conference News EAS 2018 Biology in the Back Seat: EAS 2018 Opens With Calls for a Big-Picture Approach to CVD Prevention Yael L. Maxwell May 07, 2018